MedTrace Logo

Effect of Antiemetic Timing on Nausea Severity and Patient Comfort in the Emergency Department

NCT07523230 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2026-04-27

No results posted yet for this study

Summary

Nausea is a common symptom among patients presenting to the emergency department and can negatively affect patient comfort and clinical outcomes. The timing of antiemetic administration may play a critical role in symptom control; however, evidence regarding the optimal timing remains limited. This multicenter interventional study aims to evaluate the effect of early versus delayed antiemetic administration on nausea severity and patient comfort in adult emergency department patients. Participants will be assigned to receive antiemetic treatment either within the first 30 minutes after triage or after 30 minutes. Nausea severity will be assessed using a numeric rating scale, and patient comfort will be evaluated at predefined time points. The findings of this study are expected to contribute to improving symptom management and optimizing clinical practices in emergency care settings.

Conditions

  • Nausea
  • Emergency Department Patients

Interventions

BEHAVIORAL

Antiemetic Timing

The intervention consists of adjusting the timing of routine antiemetic administration in emergency department patients without altering the type or dosage of medication. Participants are assigned to receive antiemetics either within 30 minutes (early group) or after 30 minutes (delayed group) following triage (T0), in accordance with standard clinical care. Outcome measures include nausea severity assessed using a Numeric Rating Scale (NRS, 0-10) at T0, Tpost30, and Tpost60, and comfort level assessed at T0 and Tpost60.

Sponsors & Collaborators

  • muzeyyen ataseven

    lead OTHER

Principal Investigators

  • Muzeyyen Ataseven, PhD,RN · Istanbul Medipol University, Faculty of Health Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-05
Primary Completion
2026-04-05
Completion
2026-04-05

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07523230 on ClinicalTrials.gov